Tags

Type your tag names separated by a space and hit enter

Sandostatin, a new analogue of somatostatin, reduces the metabolic changes induced by the nocturnal interruption of continuous subcutaneous insulin infusion in type 1 (insulin-dependent) diabetic patients.
Diabetologia. 1989 Nov; 32(11):801-9.D

Abstract

With the aim of assessing a new somatostatin analogue to prevent the metabolic changes induced by a 6-h nocturnal arrest of an insulin pump, nine C-peptide negative Type 1 (insulin-dependent) diabetic patients were submitted blindly to two interruptions (from 23.00 to 05.00 hours) of their continuous s.c. insulin infusion, once after a single s.c. injection at 23.00 hours of 50 micrograms SMS 201-995 (Sandostatin, Sandoz) and once after 0.9% NaCl. Plasma SMS 201-995 levels peaked at 24.00 hours and then declined with an elimination half-life averaging 144 +/- 15 min. Plasma glucagon and growth hormone levels were significantly reduced after SMS 201-995 whereas the progressive fall in plasma-free insulin levels from 23.00 to 05.00 hours was unaffected. In the control test, blood glucose levels tended to decrease slightly from 23.00 to 02.00 hours and then increased markedly from 02.00 to 05.00 hours (+5.3 +/- 1.5 mmol/l) while after SMS 201-995 they decreased significantly from 23.00 to 02.00 hours (-2.6 +/- 0.5 mmol/l), resulting in values below 3 mmol/l in seven subjects, but showed a secondary increase until 05.00 hours (+3.5 +/- 1.5 mmol vs 23.00 h; p less than 0.05 vs 0.9% NaCl). While the rises in plasma non-esterified fatty acid and glycerol levels were not reduced by SMS 201-995, the increase in plasma 3-hydroxbutyrate levels, although similar from 23.00 to 02.00 hours, was significantly reduced from 02.00 to 05.00 hours (+77 +/- 20 vs +124 +/- 31 mumols.l-1.h-1; p less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

Authors+Show Affiliations

Scheen AJ
Department of Medicine, University of Liège, Belgium.
Gillet J
No affiliation info available
Rosenthaler J
No affiliation info available
Guiot J
No affiliation info available
Henrivaux P
No affiliation info available
Jandrain B
No affiliation info available
Lefèbvre PJ
No affiliation info available

MeSH

3-Hydroxybutyric AcidAdultBlood GlucoseC-PeptideDiabetes Mellitus, Type 1Diabetic NeuropathiesDrug Administration ScheduleFatty Acids, NonesterifiedFemaleGlucagonGlycerolGrowth HormoneHumansHydroxybutyratesInsulinInsulin Infusion SystemsMaleOctreotide

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

2687064

Citation

Scheen, A J., et al. "Sandostatin, a New Analogue of Somatostatin, Reduces the Metabolic Changes Induced By the Nocturnal Interruption of Continuous Subcutaneous Insulin Infusion in Type 1 (insulin-dependent) Diabetic Patients." Diabetologia, vol. 32, no. 11, 1989, pp. 801-9.
Scheen AJ, Gillet J, Rosenthaler J, et al. Sandostatin, a new analogue of somatostatin, reduces the metabolic changes induced by the nocturnal interruption of continuous subcutaneous insulin infusion in type 1 (insulin-dependent) diabetic patients. Diabetologia. 1989;32(11):801-9.
Scheen, A. J., Gillet, J., Rosenthaler, J., Guiot, J., Henrivaux, P., Jandrain, B., & Lefèbvre, P. J. (1989). Sandostatin, a new analogue of somatostatin, reduces the metabolic changes induced by the nocturnal interruption of continuous subcutaneous insulin infusion in type 1 (insulin-dependent) diabetic patients. Diabetologia, 32(11), 801-9.
Scheen AJ, et al. Sandostatin, a New Analogue of Somatostatin, Reduces the Metabolic Changes Induced By the Nocturnal Interruption of Continuous Subcutaneous Insulin Infusion in Type 1 (insulin-dependent) Diabetic Patients. Diabetologia. 1989;32(11):801-9. PubMed PMID: 2687064.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Sandostatin, a new analogue of somatostatin, reduces the metabolic changes induced by the nocturnal interruption of continuous subcutaneous insulin infusion in type 1 (insulin-dependent) diabetic patients. AU - Scheen,A J, AU - Gillet,J, AU - Rosenthaler,J, AU - Guiot,J, AU - Henrivaux,P, AU - Jandrain,B, AU - Lefèbvre,P J, PY - 1989/11/1/pubmed PY - 1989/11/1/medline PY - 1989/11/1/entrez SP - 801 EP - 9 JF - Diabetologia JO - Diabetologia VL - 32 IS - 11 N2 - With the aim of assessing a new somatostatin analogue to prevent the metabolic changes induced by a 6-h nocturnal arrest of an insulin pump, nine C-peptide negative Type 1 (insulin-dependent) diabetic patients were submitted blindly to two interruptions (from 23.00 to 05.00 hours) of their continuous s.c. insulin infusion, once after a single s.c. injection at 23.00 hours of 50 micrograms SMS 201-995 (Sandostatin, Sandoz) and once after 0.9% NaCl. Plasma SMS 201-995 levels peaked at 24.00 hours and then declined with an elimination half-life averaging 144 +/- 15 min. Plasma glucagon and growth hormone levels were significantly reduced after SMS 201-995 whereas the progressive fall in plasma-free insulin levels from 23.00 to 05.00 hours was unaffected. In the control test, blood glucose levels tended to decrease slightly from 23.00 to 02.00 hours and then increased markedly from 02.00 to 05.00 hours (+5.3 +/- 1.5 mmol/l) while after SMS 201-995 they decreased significantly from 23.00 to 02.00 hours (-2.6 +/- 0.5 mmol/l), resulting in values below 3 mmol/l in seven subjects, but showed a secondary increase until 05.00 hours (+3.5 +/- 1.5 mmol vs 23.00 h; p less than 0.05 vs 0.9% NaCl). While the rises in plasma non-esterified fatty acid and glycerol levels were not reduced by SMS 201-995, the increase in plasma 3-hydroxbutyrate levels, although similar from 23.00 to 02.00 hours, was significantly reduced from 02.00 to 05.00 hours (+77 +/- 20 vs +124 +/- 31 mumols.l-1.h-1; p less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS) SN - 0012-186X UR - https://www.unboundmedicine.com/medline/citation/2687064/Sandostatin_a_new_analogue_of_somatostatin_reduces_the_metabolic_changes_induced_by_the_nocturnal_interruption_of_continuous_subcutaneous_insulin_infusion_in_type_1__insulin_dependent__diabetic_patients_ DB - PRIME DP - Unbound Medicine ER -